MRNA
Moderna Inc
What's their growth strategy?
Moderna sees itself as far more than a COVID company. The board’s explicit goal is to make mRNA technology a fundamental pillar of modern medicine, driving growth through innovative mRNA‑based treatments and vaccines.
The pillars for the future are:
1. Pipeline expansion
Target: 10 new products inapproval by 2027
Key candidates two examples:
mRESVIA again RSV a infectious disease similar to flu
mRNA‑4157 an oncology neo‑antigen vaccine co‑developed with Merck for lung cancer and melanoma.
Vaccines for CMV, Norovirus, and rare genetic disorders all in advanced clinical trials.
Moderna and Merck recently announced positive five-year Phase 2b adjuvant melanoma data, which showed intismeran autogene in combination with KEYTRUDA(pembrolizumab) reduced the risk of recurrence or death by 49% compared to KEYTRUDA alone. Moderna expects Phase 3 adjuvant melanoma data potentially in 2026.
2. Profitability focus and cost discipline
Aim to reach cash‑break‑even by 2028.
Aggressive cost‑cutting programm: Q4 2025 report, Moderna lowered annual operating expenses by approximately $2.2 billion in 2025, significantly surpassing their cost-reduction targets. More cost cutting in 2026 expected.
New production facilities in the United Kingdom, Canada and Australia are intended to lift gross margins by roughly 10 % over the next three years .
3. Scaling the mRNA platform
Continued optimization of the platform is expected to make therapeutics cheaper and faster to produce, potentially eliminating and reducing a wide range of infectious diseases and reducing their societal burden eventually.
4. Recent financial figures:
Market capitalization (March 2026): about 20,74 billion USD
2025 results: Total revenue for the fourth quarter of 2025 was $678 million, Product sales were $264 million in the U.S. and $381 million in international markets, Net loss was $(826) million for the fourth quarter of 2025, compared to net loss of $(1.1) billion for the fourth quarter of 2024
https://irp.cdn-website.com/89dd0539/files/uploaded/Q4+2025+Earnings-69-.pdf
These numbers illustrate that, despite short‑term losses, investors still assign a substantial value to Moderna’s long‑term pipeline and platform potential. Justified from my point of view because the potential upside is immense, and the technology platform application is showing results in clinical trials.
6. Outlook for the next decade from my point of view:
In ten years Moderna will likely be judged on the success of its oncology, infectious‑disease and rare‑disease programmes rather than on COVID‑19 sales. If the cancer‑vaccine portfolio only captures a fraction of its scientific potential, the current market‑cap could be viewed as an entry point for investors looking for upside as the pipeline matures.
I'm currently working on a list of things I missed and want to complete in the coming weeks: this includes completing research on ASML, a short piece on Roblox, some deep dive in Moderna the concerns with mRNA vaccines/the statistical misconceptions about vaccination which are very interesting to take apart as a investor. If you have suggestions for my to do list leave a comment:)
https://firstwordpharma.com/story/7061673